ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS

口腔黑色素瘤:ALPHA V BETA 3 表达和转移

基本信息

  • 批准号:
    6516516
  • 负责人:
  • 金额:
    $ 21.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-15 至 2005-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Adapted from the Investigator's Abstract): Malignant melanoma of the oral cavity is almost always fatal. The proposed work focuses on two stages in melanoma progression: invasion and metastasis, during which melanoma cells interact with the extracellular matrix primarily through integrin receptors. The vitronectin receptor alphavbeta3 is expressed by vertically invasive and metastatic cutaneous melanoma but is absent from superficial spreading melanoma and normal melanocytes in vivo. In the murine K1735 melanoma, highly metastatic cells express alphavbeta3, but not the alphavbeta5 vitronectin receptor, while poorly metastatic cells express alphavbeta5 but not alphavbeta3. Adhesion of alphavbeta3, but not alphavbeta5, to vitronectin results in the activation of FAK, c-Src, and pMAP kinase-signaling molecules implicated in cell motility and gene expression - and in increased expression of matrix metalloproteinase-2 (MMP-2). This study addresses the following questions: 1) Does expression of alphavbeta3 or alphaVbeta5 correlate with oral melanoma metastasis? Human biopsy specimens will be evaluated by immunohistochemistry and in situ hybridization for expression of alphavbeta3 or alphavbeta5. 2) Does expression of alphavbeta3 correlate with metastatic potential in murine melanoma cells? K1735 cells with differing metastatic potential will be used to generate additional metastatic variants by both transoral and hind-flank injection. The resulting tumors and variant cell lines will be evaluated for expression of alphavbeta3 and for activation of FAK, pMAP kinase, and expression of MMP-2. 3) Will overexpression of alphavbeta3 confer the metastatic phenotype to poorly metastatic melanoma cells? Poorly metastatic cells expressing beta3 by retroviral transduction will be evaluated for invasive and metastatic behavior. The effect on metastasis of expressing a constitutively active Src will also be evaluated. 4) Will decreasing alphavbeta3 receptor expression, or suppressing its function, alter the invasive and metastatic potential of melanoma cells? beta3 expression in highly metastatic cells will be reduced by both antisense and dominant negative strategies. Also, human beta3 will be expressed in poorly invasive melanoma cells, and its function suppressed by function-blocking antibody to human beta3. Finally, whether expression of a dominant-negative c-Src in a highly metastatic cell line decreases metastasis will be determined. Understanding the role beta3 plays in oral melanoma invasion and metastasis may lead to novel prognostic indicators and development of new treatment strategies.
描述(改编自研究者摘要):恶性黑色素瘤

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANIEL M RAMOS其他文献

DANIEL M RAMOS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANIEL M RAMOS', 18)}}的其他基金

ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
  • 批准号:
    6379867
  • 财政年份:
    2000
  • 资助金额:
    $ 21.94万
  • 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
  • 批准号:
    6758507
  • 财政年份:
    2000
  • 资助金额:
    $ 21.94万
  • 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
  • 批准号:
    6200152
  • 财政年份:
    2000
  • 资助金额:
    $ 21.94万
  • 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
  • 批准号:
    6619567
  • 财政年份:
    2000
  • 资助金额:
    $ 21.94万
  • 项目类别:
MATRIX REMODELING IN ORAL SQUAMOUS CELL CARCINOMA
口腔鳞状细胞癌的基质重塑
  • 批准号:
    6176024
  • 财政年份:
    1999
  • 资助金额:
    $ 21.94万
  • 项目类别:
MATRIX REMODELING IN ORAL SQUAMOUS CELL CARCINOMA
口腔鳞状细胞癌的基质重塑
  • 批准号:
    2885570
  • 财政年份:
    1999
  • 资助金额:
    $ 21.94万
  • 项目类别:
REGULATED EXPRESSION OF TENASCIN AND AVB6 IN ORAL CANCER
口腔癌中腱蛋白和 AVB6 的调控表达
  • 批准号:
    2015297
  • 财政年份:
    1997
  • 资助金额:
    $ 21.94万
  • 项目类别:
Regulatory function of fyn in oral SCC invasion
fyn在口腔鳞状细胞癌侵袭中的调节作用
  • 批准号:
    6754349
  • 财政年份:
    1997
  • 资助金额:
    $ 21.94万
  • 项目类别:
Regulatory function of fyn in oral SCC invasion
fyn在口腔鳞状细胞癌侵袭中的调节作用
  • 批准号:
    6611893
  • 财政年份:
    1997
  • 资助金额:
    $ 21.94万
  • 项目类别:
REGULATED EXPRESSION OF TENASCIN AND AVB6 IN ORAL CANCER
口腔癌中腱蛋白和 AVB6 的调控表达
  • 批准号:
    2897110
  • 财政年份:
    1997
  • 资助金额:
    $ 21.94万
  • 项目类别:

相似海外基金

A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
  • 批准号:
    10279706
  • 财政年份:
    2021
  • 资助金额:
    $ 21.94万
  • 项目类别:
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
  • 批准号:
    10693288
  • 财政年份:
    2021
  • 资助金额:
    $ 21.94万
  • 项目类别:
Study of suppressing effect by PAD4 catalytic cleft blocking antibody to rheumatoid arthritis and interstitial pneumonitis
PAD4催化裂隙阻断抗体对类风湿性关节炎和间质性肺炎抑制作用的研究
  • 批准号:
    17K09982
  • 财政年份:
    2017
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Infection-blocking antibody targets for malaria
疟疾感染阻断抗体靶点
  • 批准号:
    9247922
  • 财政年份:
    2016
  • 资助金额:
    $ 21.94万
  • 项目类别:
Infection-blocking antibody targets for malaria
疟疾感染阻断抗体靶点
  • 批准号:
    9890993
  • 财政年份:
    2016
  • 资助金额:
    $ 21.94万
  • 项目类别:
Characterization of a GPCR-blocking antibody for the treatment of breast cancer.
用于治疗乳腺癌的 GPCR 阻断抗体的表征。
  • 批准号:
    8199615
  • 财政年份:
    2011
  • 资助金额:
    $ 21.94万
  • 项目类别:
Regulation of the IL-31 function by the blocking antibody to IL-31 receptor
IL-31 受体阻断抗体对 IL-31 功能的调节
  • 批准号:
    22591230
  • 财政年份:
    2010
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Animal Testing of a Blocking Antibody of PcrV
PcrV 阻断抗体的动物试验
  • 批准号:
    6444270
  • 财政年份:
    2002
  • 资助金额:
    $ 21.94万
  • 项目类别:
The detection of blocking antibody against plasma thrombopoietin in subjects with childhood idiopathic thrombocytopenic purpura
儿童特发性血小板减少性紫癜患者血浆血小板生成素阻断抗体的检测
  • 批准号:
    13670842
  • 财政年份:
    2001
  • 资助金额:
    $ 21.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了